QQQ   386.32 (-0.93%)
AAPL   189.43 (-0.95%)
MSFT   369.14 (-1.43%)
META   320.02 (-1.48%)
GOOGL   129.27 (-1.96%)
AMZN   144.84 (-1.49%)
TSLA   235.58 (-1.36%)
NVDA   455.10 (-2.68%)
NIO   7.32 (+2.38%)
BABA   73.03 (-1.30%)
AMD   118.57 (-2.32%)
T   16.67 (-0.60%)
F   10.70 (+1.13%)
MU   74.29 (-2.16%)
CGC   0.76 (+22.72%)
GE   121.50 (-0.82%)
DIS   92.01 (-0.62%)
AMC   7.50 (+9.18%)
PFE   29.25 (+1.18%)
PYPL   59.85 (+0.34%)
XOM   102.43 (-0.54%)
QQQ   386.32 (-0.93%)
AAPL   189.43 (-0.95%)
MSFT   369.14 (-1.43%)
META   320.02 (-1.48%)
GOOGL   129.27 (-1.96%)
AMZN   144.84 (-1.49%)
TSLA   235.58 (-1.36%)
NVDA   455.10 (-2.68%)
NIO   7.32 (+2.38%)
BABA   73.03 (-1.30%)
AMD   118.57 (-2.32%)
T   16.67 (-0.60%)
F   10.70 (+1.13%)
MU   74.29 (-2.16%)
CGC   0.76 (+22.72%)
GE   121.50 (-0.82%)
DIS   92.01 (-0.62%)
AMC   7.50 (+9.18%)
PFE   29.25 (+1.18%)
PYPL   59.85 (+0.34%)
XOM   102.43 (-0.54%)
QQQ   386.32 (-0.93%)
AAPL   189.43 (-0.95%)
MSFT   369.14 (-1.43%)
META   320.02 (-1.48%)
GOOGL   129.27 (-1.96%)
AMZN   144.84 (-1.49%)
TSLA   235.58 (-1.36%)
NVDA   455.10 (-2.68%)
NIO   7.32 (+2.38%)
BABA   73.03 (-1.30%)
AMD   118.57 (-2.32%)
T   16.67 (-0.60%)
F   10.70 (+1.13%)
MU   74.29 (-2.16%)
CGC   0.76 (+22.72%)
GE   121.50 (-0.82%)
DIS   92.01 (-0.62%)
AMC   7.50 (+9.18%)
PFE   29.25 (+1.18%)
PYPL   59.85 (+0.34%)
XOM   102.43 (-0.54%)
QQQ   386.32 (-0.93%)
AAPL   189.43 (-0.95%)
MSFT   369.14 (-1.43%)
META   320.02 (-1.48%)
GOOGL   129.27 (-1.96%)
AMZN   144.84 (-1.49%)
TSLA   235.58 (-1.36%)
NVDA   455.10 (-2.68%)
NIO   7.32 (+2.38%)
BABA   73.03 (-1.30%)
AMD   118.57 (-2.32%)
T   16.67 (-0.60%)
F   10.70 (+1.13%)
MU   74.29 (-2.16%)
CGC   0.76 (+22.72%)
GE   121.50 (-0.82%)
DIS   92.01 (-0.62%)
AMC   7.50 (+9.18%)
PFE   29.25 (+1.18%)
PYPL   59.85 (+0.34%)
XOM   102.43 (-0.54%)

Bio-Rad Laboratories Stock Price, News & Analysis (NYSE:BIO)

$309.05
+2.05 (+0.67%)
(As of 12/4/2023 ET)
Compare
Today's Range
$302.66
▼
$310.46
50-Day Range
$269.37
▼
$365.34
52-Week Range
$261.59
▼
$509.62
Volume
437,498 shs
Average Volume
207,158 shs
Market Capitalization
$9.01 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$533.00
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability

Bio-Rad Laboratories MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
72.5% Upside
$533.00 Price Target
Short Interest
Healthy
2.82% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.54
Upright™ Environmental Score
News Sentiment
-0.15mentions of Bio-Rad Laboratories in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$195,874 Sold Last Quarter
Proj. Earnings Growth
7.24%
From $11.60 to $12.44 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.58 out of 5 stars

Medical Sector

197th out of 952 stocks

Analytical Instruments Industry

8th out of 29 stocks

See Top Rated MarketRank™ Stocks Here

BIO stock logo

About Bio-Rad Laboratories Stock (NYSE:BIO)

Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

BIO Stock Price History

BIO Stock News Headlines

December 4, 2023 | benzinga.com
Digital PCR (dPCR) and Quantitative PCR (qPCR) Market Size & Share to Surpass USD 7.5 billion by 2031 | Analysis by Transparency Market Research
November 21, 2023 | benzinga.com
DNA Testing and Diagnostics Market to Witness Steady Growth at 4.8% CAGR
December 4, 2023 | Wealthpress (Ad)
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
November 20, 2023 | benzinga.com
Blood Screening Market worth $3.4 billion by 2028
November 20, 2023 | finance.yahoo.com
Implied Volatility Surging for On Bio-Rad Laboratories (BIO) Stock Options
October 30, 2023 | gurufocus.com
The Bio-Rad Laboratories Inc (BIO) Company: A Short SWOT Analysis
October 27, 2023 | msn.com
Why Is Clinical Diagnostic-Focused Bio-Rad Stock Trading Lower Today?
October 27, 2023 | finance.yahoo.com
Bio-Rad Laboratories, Inc. (NYSE:BIO) Q3 2023 Earnings Call Transcript
December 4, 2023 | DTI Trader (Ad)
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
October 26, 2023 | marketwatch.com
Bio-Rad Shares Drop After Company Reports 3Q Results
October 26, 2023 | finance.yahoo.com
Bio-Rad Laboratories Inc (BIO) Q3 2023 Earnings: A Detailed Review
October 25, 2023 | finance.yahoo.com
Medical Device Stocks' Q3 Earnings Due on Oct 26: BSX, BIO & More
October 25, 2023 | msn.com
Bio-Rad: Business Returns Aren't Economically Valuable, Sartorius Now A Hindrance
October 17, 2023 | marketwatch.com
Bio-Rad Laboratories CFO Ilan Daskal to Resign
October 17, 2023 | msn.com
Bio-Rad Laboratories announces resignation of CFO Ilan Daskal
October 17, 2023 | finance.yahoo.com
Unveiling Bio-Rad Laboratories' Value: Is It Really Priced Right? A Comprehensive Guide
October 9, 2023 | finance.yahoo.com
The past three years for Bio-Rad Laboratories (NYSE:BIO) investors has not been profitable
October 5, 2023 | benzinga.com
Blood Group Typing Market worth $3.0 billion | MarketsandMarkets
October 5, 2023 | finance.yahoo.com
Bio-Rad to Report Third Quarter 2023 Financial Results on Thursday, October 26, 2023
October 4, 2023 | benzinga.com
Microfluidics Market Size to Expand at a CAGR of 16.5% to Reach Valuation of USD 73.16 Billion by 2028 | Brandessence Market Research
October 4, 2023 | benzinga.com
DNA Extraction, Isolation, Purification Market Worth $6.10 Billion, Globally, by 2030 - Exclusive Report by The Insight Partners
October 3, 2023 | finance.yahoo.com
Implied Volatility Surging for Bio-Rad (BIO) Stock Options
September 28, 2023 | finance.yahoo.com
Bio-Rad Introduces the IH-500, a Fully Automated Random Access System for Blood Typing and Screening
September 28, 2023 | finance.yahoo.com
ResMed (RMD) Stock Jumps 3.8%: Will It Continue to Soar?
September 19, 2023 | msn.com
How California can improve safety and transparency of privately run bio labs
September 14, 2023 | benzinga.com
Global Laboratory Disposable Market Size to Forecasted to Surge $18 Billion Growth by 2030, Exhibit a CAGR of 3.2%
September 8, 2023 | finance.yahoo.com
Unveiling Bio-Rad Laboratories (BIO)'s Value: Is It Really Priced Right? A Comprehensive Guide
See More Headlines
Receive BIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bio-Rad Laboratories and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
10/26/2023
Today
12/04/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/15/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Analytical instruments
Sub-Industry
Life Sciences Tools & Services
Sector
Medical
Current Symbol
NYSE:BIO
CUSIP
09057220
CIK
12208
Web
www.bio-rad.com
Phone
(510) 724-7000
Fax
510-741-5817
Employees
8,200
Year Founded
1952

Price Target and Rating

Average Stock Price Target
$533.00
High Stock Price Target
$550.00
Low Stock Price Target
$524.00
Potential Upside/Downside
+72.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($5.85)
Trailing P/E Ratio
N/A
Forward P/E Ratio
26.64
P/E Growth
N/A
Net Income
$-3,627,530,000.00
Net Margins
-5.86%
Pretax Margin
-6.88%
Return on Equity
3.91%
Return on Assets
2.78%

Debt

Debt-to-Equity Ratio
0.14
Current Ratio
5.64
Quick Ratio
4.25

Sales & Book Value

Annual Sales
$2.80 billion
Price / Sales
3.21
Cash Flow
$14.72 per share
Price / Cash Flow
21.00
Book Value
$324.89 per share
Price / Book
0.95

Miscellaneous

Outstanding Shares
29,150,000
Free Float
24,173,000
Market Cap
$9.01 billion
Optionable
Optionable
Beta
0.93

Social Links

Beginner's Guide to Pot Stock Investing Cover
Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions














BIO Stock Analysis - Frequently Asked Questions

Should I buy or sell Bio-Rad Laboratories stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bio-Rad Laboratories in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BIO shares.
View BIO analyst ratings or view top-rated stocks.

What is Bio-Rad Laboratories' stock price target for 2024?

3 Wall Street research analysts have issued 1 year price targets for Bio-Rad Laboratories' shares. Their BIO share price targets range from $524.00 to $550.00. On average, they predict the company's share price to reach $533.00 in the next twelve months. This suggests a possible upside of 72.5% from the stock's current price.
View analysts price targets for BIO or view top-rated stocks among Wall Street analysts.

How have BIO shares performed in 2023?

Bio-Rad Laboratories' stock was trading at $420.49 at the beginning of the year. Since then, BIO stock has decreased by 26.5% and is now trading at $309.05.
View the best growth stocks for 2023 here.

Are investors shorting Bio-Rad Laboratories?

Bio-Rad Laboratories saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 572,100 shares, an increase of 36.9% from the October 31st total of 418,000 shares. Based on an average daily trading volume, of 235,900 shares, the short-interest ratio is currently 2.4 days. Approximately 2.8% of the company's shares are short sold.
View Bio-Rad Laboratories' Short Interest.

When is Bio-Rad Laboratories' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 15th 2024.
View our BIO earnings forecast.

How were Bio-Rad Laboratories' earnings last quarter?

Bio-Rad Laboratories, Inc. (NYSE:BIO) posted its quarterly earnings results on Thursday, October, 26th. The medical research company reported $2.33 earnings per share for the quarter, missing the consensus estimate of $2.87 by $0.54. The medical research company earned $632.10 million during the quarter, compared to analysts' expectations of $689.50 million. Bio-Rad Laboratories had a positive trailing twelve-month return on equity of 3.91% and a negative net margin of 5.86%. The company's revenue was down 7.1% compared to the same quarter last year. During the same period in the prior year, the business posted $2.60 EPS.
Read the conference call transcript.

What ETFs hold Bio-Rad Laboratories' stock?

ETFs with the largest weight of Bio-Rad Laboratories (NYSE:BIO) stock in their portfolio include ETFMG Treatments Testing and Advancements ETF (GERM), Harbor Health Care ETF (MEDI), Putnam BioRevolution ETF (SYNB), Principal Healthcare Innovators ETF (BTEC), Invesco S&P 500 Equal Weight Health Care ETF (RYH), Invesco S&P 500 Equal Weight Health Care ETF (RSPH), ROBO Global Healthcare Technology and Innovation ETF (HTEC) and First Trust Indxx Medical Devices ETF (MDEV).

What is Norman Schwartz's approval rating as Bio-Rad Laboratories' CEO?

325 employees have rated Bio-Rad Laboratories Chief Executive Officer Norman Schwartz on Glassdoor.com. Norman Schwartz has an approval rating of 84% among the company's employees.

What other stocks do shareholders of Bio-Rad Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Rad Laboratories investors own include BioMarin Pharmaceutical (BMRN), Incyte (INCY), Puma Biotechnology (PBYI), AbbVie (ABBV), NVIDIA (NVDA), Broadcom (AVGO), Johnson & Johnson (JNJ), Advanced Micro Devices (AMD), Alibaba Group (BABA) and Intel (INTC).

Who are Bio-Rad Laboratories' major shareholders?

Bio-Rad Laboratories' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Veritas Asset Management LLP (3.83%), Brown Advisory Inc. (3.29%), Westfield Capital Management Co. LP (1.24%), Earnest Partners LLC (1.21%), Invesco Ltd. (1.18%) and Massachusetts Financial Services Co. MA (1.11%). Insiders that own company stock include Ajit Ramalingam, Annette Tumolo, Ilan Daskal, Michael Crowley, Timothy S Ernst and Timothy S Ernst.
View institutional ownership trends.

How do I buy shares of Bio-Rad Laboratories?

Shares of BIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

Does Bio-Rad Laboratories have any subsidiaries?
The following companies are subsidiares of Bio-Rad Laboratories: (f/k/a Bio-Rad Laboratories (Israel) Inc.), BIO-RAD spol. s r.o., Bio-Metrics (U.K.) Limited, Bio-Rad, Bio-Rad (Shanghai) Life Science Research & Development Co. Ltd., Bio-Rad 1, Bio-Rad AbD Serotec GmbH, Bio-Rad AbD Serotec Ltd, Bio-Rad China Ltd., Bio-Rad Denmark ApS, Bio-Rad Europe GmbH, Bio-Rad Export LLC, Bio-Rad Finland Oy (f/k/a DiaMed Fennica Oy), Bio-Rad France, Bio-Rad France Holding, Bio-Rad Germany Holding GmbH, Bio-Rad Haifa Ltd., Bio-Rad Holdings LLC, Bio-Rad Hungary Trading LLC, Bio-Rad IHC Europe GmbH, Bio-Rad Innovations, Bio-Rad Korea Ltd., Bio-Rad Laboratories (Canada) Limited, Bio-Rad Laboratories (India) Private Limited, Bio-Rad Laboratories (Pty) Ltd, Bio-Rad Laboratories (Rishon) Inc., Bio-Rad Laboratories (Shanghai) Co. Ltd., Bio-Rad Laboratories (Singapore) Pte Ltd, Bio-Rad Laboratories AB, Bio-Rad Laboratories AG, Bio-Rad Laboratories B.V., Bio-Rad Laboratories Ges.m.b.H., Bio-Rad Laboratories GmbH, Bio-Rad Laboratories K.K., Bio-Rad Laboratories Limited, Bio-Rad Laboratories Logistik GmbH, Bio-Rad Laboratories Ltd., Bio-Rad Laboratories M.EPE, Bio-Rad Laboratories NV, Bio-Rad Laboratories Pty Ltd, Bio-Rad Laboratories S.A., Bio-Rad Laboratories S.r.l., Bio-Rad Laboratories SAS, Bio-Rad Laboratories-Aparelhos e Reagentes para Laboratórios Lda, Bio-Rad Laboratorii OOO, Bio-Rad Laboratórios Brasil Ltda., Bio-Rad Luxembourg S.à r.l., Bio-Rad Medical Diagnostics GmbH, Bio-Rad Middle East FZ-LLC, Bio-Rad Norway AS, Bio-Rad Pacific Limited, Bio-Rad Pasteur, Bio-Rad Polska Sp. z o.o., Bio-Rad QL Inc., Bio-Rad S.A., Bio-Rad Services France, Bio-Rad Services UK Limited, Biotest - Businesses, Blackhawk Biosystems, Bridger Technologies Inc., Celsee, Ciphergen Biosystems - ProteinChip Systems Business, DiaMed (G.B.) Ltd, DiaMed (Schweiz) GmbH, DiaMed Benelux NV, DiaMed Diagnostika Deutschland GmbH, DiaMed France SA, DiaMed GmbH, DiaMed Holding AG, DiaMed Holding GmbH, DiaMed Latino-América S.A., DiaMed S.E.A. Limited, DiaMed Österreich GmbH, Distribudora de Analítica para la Medicina Ibérica S.A.U., Dropworks Inc., GnuBIO Inc., Helix Diagnostics, IMV Medical Information Division Inc., International Marketing Ventures Ltd., MJ GeneWorks, Propel Labs - Cell Sorting System Division, QuantaLife, Quantase Ltd., Raindance Technologies Limited, Raindance Techologies Inc., Research Specialties for Laboratories NV, Respiratory Diagnostics Inc., and Wuxi BioCanal Nano Technology Co. Ltd..
Read More
This page (NYSE:BIO) was last updated on 12/4/2023 by MarketBeat.com Staff

My Account -